[Combination of transcatheter arterial infusion of SMANCS and embolization (SMANCS-TAE) for hepatocellular carcinoma].
Patients with unresectable hepatocellular carcinoma (hepatoma) with hypervascularity were treated by SMANCS-TAE, which was performed by a superselective catheterization technique to inject gelatin sponge particles after administration of SMANCS. In 24 of 30 (80%) patients of first hepatoma treated by SMANCS-TAE, Grade 4 was obtained after about 1.5 (1-3) courses. The 2-year survival rate was 33%. SMANCS-TAE appears to have the same potential and safety as Lipiodol-TAE, treated selectively. Moreover, we can reduce the course of treatment and obtain good QOL of hepatoma patients except in advanced cases (vp 3 or T 4).